Joshua R. Lamstein - 31 Jul 2021 Form 4 Insider Report for Scopus BioPharma Inc.

Role
Chairman, Director, 10%+ Owner
Signature
/s/ Joshua R. Lamstein
Issuer symbol
SCPS on OTC
Transactions as of
31 Jul 2021
Net transactions value
-$7,500
Form type
4
Filing time
03 Aug 2021, 18:49:13 UTC
Previous filing
27 Jul 2021
Next filing
23 Aug 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SCPS Convertible Notes Other $981 $8,481 31 Jul 2021 W Warrant 1,963 $0.5000 Direct F1
transaction SCPS Convertible Notes Conversion of derivative security $8,481 $0 31 Jul 2021 W Warrant 16,963 $0.5000 Direct F2
transaction SCPS W Warrants Other +16,963 +120% 31,131 31 Jul 2021 B Unit 16,963 $4.00 Direct F3, F4, F5
transaction SCPS W Warrants Other +1,068,016 1,068,016 31 Jul 2021 B Unit 1,068,016 $4.00 SCPS/Strategic Capital Partners LLC F4, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents accrued interest on the Convertible Notes through and including July 31, 2021 (the "Maturity Date").
F2 Represents the total outstanding principal amount and accrued interest on the Convertible Notes through and including the Maturity Date that were converted into W Warrants on such date. No additional consideration was required in connection with such conversion.
F3 Represents the W Warrants issued upon conversion of the total outstanding principal amount and accrued interest on the Convertible Notes through and including the Maturity Date. No additional consideration was required in connection with such conversion.
F4 Each W Warrant is exercisable for one B Unit. Starting on April 1, 2022, each B Unit can be separated into one share of common stock and one Z Warrant. Each Z Warrant is exercisable for one share of common stock with an exercise price of $5.00 per share. The Z Warrant will become exercisable on July 1, 2022 and will expire on June 30, 2027.
F5 Includes 14,168 W Warrants that were previously reported on the reporting person's Form 3 filed with the SEC on December 15, 2020.
F6 Represents W Warrants held by SCPS/Strategic Capital Partners LLC, of which Mr. Lamstein is a co-manager. Accordingly, he is deemed to have shared voting and dispositive power over the securities held by such entity. Mr. Lamstein disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.